Iowa

Opening an Iowa account

An Iowa practice opens an account by submitting its National Provider Identifier, which Precision Biologics checks against the NPPES registry before approving the first order. Cryopreserved Wharton's jelly and exosome formats ship overnight on dry ice in validated containers; lyophilized formats ship ambient per the insert that accompanies each lot.

Every lot carries its own identifier, and the receiving clinic is responsible for tracking use at the patient-record level once product arrives. A peer-to-peer call with a Precision Biologics contact is available for questions about documentation and sourcing, not for clinical guidance.

What to confirm on your end

Before an Iowa clinic places its first order, staff should verify the practice's standing with the Iowa Board of Medicine, confirm whether a medspa location's services require a documented medical-director or supervising-physician arrangement, and check with the relevant state pharmacy or facility licensing authority about storage or handling requirements for biologic products at that site.

Clinics should also route the intended use of a given product past their own healthcare counsel; Precision Biologics does not advise on dosing, protocols, or whether a specific use fits within an existing license. Certificates of analysis, donor eligibility summaries, and lot release records are available to support that internal review.

Des Moines and Davenport, by the numbers

Iowa interest in these product categories is concentrated around Des Moines and Davenport. NPPES registry data for those two cities lists roughly 49 providers under orthopedic taxonomies, 52 under pain management, and 25 under aesthetic-related taxonomies.

Those counts describe registered providers in Des Moines and Davenport specifically - they are not a statewide figure, not a count of current customers, and not a projection of demand, and should be read only as a general reference point.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.